Transcenta Therapeutics, a Princeton, New Jersey-based biopharmaceutical company, has entered into a technology licensing and strategic collaboration agreement with China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics covering technologies used in continuous bioprocessing.

Under the agreement, Transcenta and its subsidiary HJB will grant WuXi Biologics and its affiliates a nonexclusive license to technologies related to Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform and ExcelPro cell culture media. Transcenta will receive an upfront payment of RMB 10 million and is eligible for additional milestone payments tied to specified conditions.

The HiCB platform combines intensified continuous perfusion upstream processing with hybrid continuous downstream purification. According to Transcenta, the approach is designed to increase manufacturing productivity compared with conventional fed-batch processing, while maintaining product quality through shorter process residence times and controlled culture conditions.

The collaboration will make WuXi Biologics a strategic partner for chemistry, manufacturing and controls (CMC) development and manufacturing support for molecules in Transcenta’s development pipeline. The companies also plan to apply the licensed technologies to additional biologics programs.

For Transcenta, the agreement expands the external application of its continuous bioprocessing technology beyond its internal development programs. The company said it plans to pursue additional licensing and industry partnerships for the platform.

The collaboration comes as WuXi Biologics continues to expand its global manufacturing network and invest in technologies for complex biologics. In its first-half 2026 results, the company reported that complex modalities, including antibody-drug conjugates and bispecific and multispecific antibodies, accounted for more than half of revenue and that it was supporting more than 1,000 integrated client projects.

WuXi Biologics also is expanding manufacturing capacity in the U.S. and overseas. The CRDMO is progressing construction of a 36,000-liter commercial manufacturing facility in Worcester, Massachusetts, while upgrading its Cranbury, New Jersey site for commercial manufacturing. A drug product facility under construction in Singapore is expected to add approximately 100 million annual prefilled syringe and vial units when operations begin in 2027.